A small practical choice in menopause care can matter to patients

Women’s midlife and older women · Source date: November 1, 2026 · Evidence: Small randomized noninferiority trial · Primary source

For postmenopausal patients with recurrent urinary tract infections, the way a prescribed topical estrogen treatment is applied can affect comfort and adherence. The TAPER trial randomized 114 participants, mean age 71, to intravaginal estradiol cream or periurethral application and followed them for six months. It asked whether an easier route could preserve prevention benefit.

The proportion without a UTI at six months was 52.6% after intravaginal application and 50.9% after periurethral application. The risk difference was −1.75 percentage points, with a 95% confidence interval from −20.0 to +17.0 points. The trial’s noninferiority margin was unusually permissive at 25 percentage points, the study was unblinded and single-center, and it did not compare estrogen with no treatment. It found more reported vaginal itching at three months in the intravaginal group (24.0% versus 2.4%).

Convenience, tolerability and actual infection recurrence matter. The wide confidence interval does not establish that the two routes work identically for every patient.

certainty; do not extrapolate to untreated patients.